TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients (TRADE HF)
Heart Failure, Congestive
About this trial
This is an interventional treatment trial for Heart Failure, Congestive
Eligibility Criteria
Inclusion Criteria: chronic symptomatic HF despite stable, optimal drug therapy indication for a cardiac resynchronisation device with defibrillator backup according to current guidelines patients implanted with cardiac resynchronization device with dual (atrial and ventricular) defibrillation capabilities Exclusion Criteria: Chronic atrial fibrillation Valvular disease patients who underwent or are planned for ablation of atrial fibrillation cerebral vascular accident/transient ischemic attack within 12 months from implant which lead to relevant impairment preexisting unipolar pacemaker
Sites / Locations
- Istituto di Clinica Medica I° e Cardiologia A.O.C.
- Azienda Ospedale S. Anna
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Device managed arm
Traditional arm
Device-managed therapy arm. Shock therapy for atrial arrhythmias is delivered automatically from the device.
Traditional therapy arm. In this arm, therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment. Therefore, patients who will experience symptoms at home, will refer to their center, eventually hospitalized and treated for atrial arrhythmias.